Chlamydia Treatment Market Size & Share, by Test Type (Culture Tests, Nucleic Acid Amplification Test (NAAT), Direct Fluorescent Antibody Test, Serology Tests); Route of Administration (Oral, Injectable); End-user (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2030

  • Report ID: 3579
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

Global Chlamydia Treatment Market Highlights 2022 – 2030

The global chlamydia treatment market is estimated to garner a large amount of revenue and grow at a CAGR of ~10% over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the increasing prevalence chlamydia and other sexually transmitted diseases, and rise in demand for screening of the disease among people all around the world. According to the World Health Organization, each year, there are an estimated 376 million new infections with 1 of 4 STIs: chlamydia, gonorrhea, syphilis and trichomoniasis. Also, more than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. Along with these, growing number of government initiatives and free diagnostic camps for spreading awareness about sexually transmitted infections is also predicted to be a significant factor driving market growth in the near future. Furthermore, favorable reimbursement policies for companies are evaluated to give impetus to research and development activities associated with the development of novel drugs, which in turn is projected to offer lucrative opportunities for market growth in the forthcoming years.

Chlamydia Treatment Market

Get more information on this reportDownload Sample PDF

The market is segmented by test type into culture tests, nucleic acid amplification test (NAAT), direct fluorescent antibody test, serology tests, and others, out of which, the nucleic acid amplification test (NAAT) segment is anticipated to hold the largest share in the global chlamydia treatment market. This can be accounted to the high accuracy of the test in screening the disease. Apart from these, NAATs allow screening of large number of males and females using self-collected vaginal swabs or using urine without the requirement of a pelvic examination. Additionally, on the basis of route of administration, the oral segment is assessed to acquire the largest share over the forecast period owing to the non-invasive nature, ease of convenience, and cost-effectiveness of this type of route for drug administration. 

Major Macro-Economic Indicators Impacting the Market Growth

Healthcare Expenditure

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Chlamydia Treatment Market Regional Synopsis

On the basis of geographical analysis, the global chlamydia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the growing demand for medical screening and burgeoning need for raising awareness about STIs. In addition, rapid growth of biopharmaceutical industry and rising government support for improving the healthcare infrastructure are also anticipated to drive the region’s market growth in the future. Moreover, the market in North America is projected to grab the largest share during the forecast period ascribing to the high adoption rate of medical screening, high prevalence of STDs, and presence of a large number of pharmaceutical and biopharmaceutical companies in the region. As per the Centers for Disease Control and Prevention, in 2019, a total of 1,808,703 cases of Chlamydia trachomatis infection were reported, making it the most common notifiable condition in the United States for that year.

Chlamydia Treatment Market

Get more information on this reportDownload Sample PDF

The global chlamydia treatment market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global chlamydia treatment market includes the following segments:

By Test Type

  • Culture Tests
  • Nucleic Acid Amplification Test (NAAT)
  • Direct Fluorescent Antibody Test
  • Serology Tests
  • Others

By Route of Administration

  • Oral
  • Injectable
  • Others

By End User

  • Hospitals
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Others

Growth Drivers

  • Increasing Prevalence of Sexually Transmitted Diseases Globally
  • Rising Demand for Screening of the Disease


  • Social Stigma Associated with STIs

Top Featured Companies Dominating the Market

  • Pfizer, Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • GlaxoSmithKline Plc
  • AstraZeneca plc
  • Gilead Sciences Inc.
  • Sanofi Group
  • Teva Pharmaceuticals
  • Novartis AG
  • Abbott Laboratories
  • Hologic, Inc.
  • Johnson & Johnson Services, Inc.


In the News

  • October 2019- GSK began the phase III clinical program for new chemical class of antibiotic, gepotidacin, in patients with uncomplicated urinary tract infection and STDs.

  • August 2019- Statens Serum Institut, completed the clinical phase 1 trial for first-generation vaccine candidate (CTH522), which is aimed to provide a preventive therapy for chlamydia infection.

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 3579
  • Published Date: Feb 07, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving market growth are increasing prevalence of sexually transmitted diseases globally and rising demand for screening of chlamydia.

The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2022 – 2030.

Social stigma associated with STIs is estimated to hamper the market growth.

Asia Pacific will provide more business opportunities for market growth owing to the growing demand for medical screening and burgeoning need for raising awareness about STIs.

The major players in the market are Pfizer, Inc., GlaxoSmithKline Plc, AstraZeneca plc, Gilead Sciences Inc., Sanofi Group, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by test type, route of administration, end user, and by region.

The oral segment is anticipated to hold largest market size and is estimated to grow at a notable CAGR over the forecast period and display significant growth opportunities.

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying